1
|
Liu Y, Li X, Liang A. Current research progress of local drug delivery systems based on biodegradable polymers in treating chronic osteomyelitis. Front Bioeng Biotechnol 2022; 10:1042128. [PMID: 36507256 PMCID: PMC9729283 DOI: 10.3389/fbioe.2022.1042128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2022] [Accepted: 11/14/2022] [Indexed: 11/25/2022] Open
Abstract
Chronic osteomyelitis is one of the most challenging diseases in orthopedic treatment. It is usually treated with intravenous antibiotics and debridement in clinical practice, which also brings systemic drug side effects and bone defects. The local drug delivery system of antibiotics has the characteristics of targeted slow release to the lesion site, replacing systemic antibiotics and reducing the toxic and side effects of drugs. It can also increase the local drug concentration, achieve sound bacteriostatic effects, and promote bone healing and formation. Currently, PMMA beads are used in treating chronic osteomyelitis at home and abroad, but the chain beads need to be removed after a second operation, inconveniences patients. Biodegradable materials have been extensively studied as optimal options for antibiotic encapsulation and delivery, bringing new hope for treating chronic osteomyelitis. This article reviews the research progress of local drug delivery systems based on biodegradable polymers, including natural and synthetic ones, in treating chronic osteomyelitis.
Collapse
Affiliation(s)
- Yixiu Liu
- Department of Orthopaedics, The Central Hospital Affiliated to Shenyang Medical College, Shenyang, China,Shenyang Clinical Research Center for Hand and Foot, Shenyang, China
| | - Xu Li
- Department of Orthopaedics, The Central Hospital Affiliated to Shenyang Medical College, Shenyang, China,Shenyang Clinical Research Center for Hand and Foot, Shenyang, China
| | - A. Liang
- Department of Orthopaedics, The Central Hospital Affiliated to Shenyang Medical College, Shenyang, China,Shenyang Clinical Research Center for Hand and Foot, Shenyang, China,*Correspondence: A. Liang,
| |
Collapse
|
2
|
Preparation of Recombinant Human Collagen III Protein Hydrogels with Sustained Release of Extracellular Vesicles for Skin Wound Healing. Int J Mol Sci 2022; 23:ijms23116289. [PMID: 35682968 PMCID: PMC9181212 DOI: 10.3390/ijms23116289] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 05/18/2022] [Accepted: 06/01/2022] [Indexed: 11/25/2022] Open
Abstract
Existing treatment methods encounter difficulties in effectively promoting skin wound healing, making this a serious challenge for clinical treatment. Extracellular vesicles (EVs) secreted by stem cells have been proven to contribute to the regeneration and repair of wound tissue, but they cannot be targeted and sustained, which seriously limits their current therapeutic potential. The recombinant human collagen III protein (rhCol III) has the advantages of good water solubility, an absence of hidden viral dangers, a low rejection rate and a stable production process. In order to achieve a site-specific sustained release of EVs, we prepared a rhCol III hydrogel by cross-linking with transglutaminase (TGase) from Streptomyces mobaraensis, which has a uniform pore size and good biocompatibility. The release profile of the rhCol III-EVs hydrogel confirmed that the rhCol III hydrogel could slowly release EVs into the external environment. Herein, the rhCol III-EVs hydrogel effectively promoted macrophage changing from type M1 to type M2, the migration ability of L929 cells and the angiogenesis of human umbilical vein endothelial cells (HUVECs). Furthermore, the rhCol III-EVs hydrogel is shown to promote wound healing by inhibiting the inflammatory response and promoting cell proliferation and angiogenesis in a diabetic rat skin injury model. The reported results indicate that the rhCol III-EVs hydrogel could be used as a new biological material for EV delivery, and has a significant application value in skin wound healing.
Collapse
|
3
|
Rippon MG, Forster J, Rogers AA. Hydro-responsive wound dressings for treating hard-to-heal wounds: a narrative review of the clinical evidence—part 2. J Wound Care 2022; 31:330-338. [DOI: 10.12968/jowc.2022.31.4.330] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
This narrative clinical review summarises the key evidence in support for the use of a hydro-responsive wound dressing, HydroTac (HRWD-2, PAUL HARTMANN AG, Germany) to address key aspects associated with the treatment of both acute and hard-to-heal wounds. This review demonstrates how HRWD-2 can be used in general to address the challenges presented by a wide range of wound types and skin injuries. It highlights the ability of HRWD-2 to regulate an optimal moist wound environment that promotes wound progression and healing. Key aspects covered in this review include the dressing's ability to: promote certain phases of the wound healing response (for example, re-epithelialisation) address the concepts and needs for wound progression as set out in the TIME wound management framework provide an optimal hydration level reduce tissue trauma and pain at dressing change.
Collapse
Affiliation(s)
- Mark G Rippon
- University of Huddersfield, Queensgate, Huddersfield, UK
| | - Jan Forster
- Wound Center Links der Weser, 28277 Bremen, Germany
| | | |
Collapse
|
4
|
Chen X, Wu J, Cao X, Jiang H, Wu Z, Zeng Z, Chen H, Zhang J. The role of gel wound dressings loaded with stem cells in the treatment of diabetic foot ulcers. Am J Transl Res 2021; 13:13261-13272. [PMID: 35035674 PMCID: PMC8748097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2021] [Accepted: 11/03/2021] [Indexed: 06/14/2023]
Abstract
Diabetic foot ulcers (DFUs) are a serious complication of diabetes and the main cause of nontraumatic lower limb amputations, resulting in a serious economic burden on society. The main causes of DFUs include peripheral neuropathy, foot deformity, chronic inflammation, and peripheral artery disease. There are many clinical approaches for the treatment of DFUs, but they are all aimed at addressing a single aetiological factor. Stem cells (SCs), which express many cytokines and a variety of nerve growth factors and modulate immunological function in the wound, may accelerate DFU healing by promoting angiogenesis, cell proliferation, and nerve growth and regulating the inflammatory response. However, the survival time of SCs without scaffold support in the wound is short. Multifunctional gel wound dressings play a critical role in skin wound healing due to their ability to maintain SC survival for a long time, provide moisture and prevent electrolyte and water loss in DFUs. Among the many methods for clinical treatment of DFUs, the most successful one is therapy with gel dressings loaded with SCs. To accelerate DFU healing, gel wound dressings loaded with SCs are needed to promote the survival and migration of SCs and increase wound contraction. This review summarizes the research advancements regarding multifunctional gel wound dressings and SCs in the treatment of DFU to demonstrate the effectiveness and safety of this combinational therapeutic strategy.
Collapse
Affiliation(s)
- Xionglin Chen
- Department of Histology & Embryology and Medical Genetics, School of Medicine, Jiujiang UniversityJiujiang 332000, Jiangxi, China
| | - Jianfang Wu
- Department of Pathogenic Biology and Immunology, School of Medicine, Jiujiang UniversityJiujiang 332000, Jiangxi, China
| | - Xiaoming Cao
- Department of Anatomy, School of Medicine, Jiujiang UniversityJiujiang 332000, Jiangxi, China
| | - He Jiang
- Department of Histology & Embryology and Medical Genetics, School of Medicine, Jiujiang UniversityJiujiang 332000, Jiangxi, China
| | - Zhiren Wu
- Department of Preventive Medicine, Grade 2019, School of Medicine, Jiujiang UniversityJiujiang 332000, Jiangxi, China
| | - Zidu Zeng
- Department of Preventive Medicine, Grade 2019, School of Medicine, Jiujiang UniversityJiujiang 332000, Jiangxi, China
| | - Hui Chen
- Department of Anatomy, School of Medicine, Jiujiang UniversityJiujiang 332000, Jiangxi, China
| | - Jie Zhang
- Department of Histology & Embryology and Medical Genetics, School of Medicine, Jiujiang UniversityJiujiang 332000, Jiangxi, China
| |
Collapse
|